The Multiple Myeloma Drug Market Will Experience Robust 5.6 Percent Annual Growth from 2010 to 2020

The Multiple Myeloma Drug Market Will Experience Robust 5.6 Percent Annual Growth from 2010 to 2020

Further Penetration of Revlimid Into the First-Line Setting and the Launch of Premium-Priced Emerging Therapies Will Drive Growth, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by further penetration of Celgene's Revlimid into the first-line setting and the launch of premium-priced emerging therapies, the multiple myeloma drug market will experience robust 5.6 percent annual growth from 2010 to 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

"Velcade will remain the second highest selling agent but will suffer from the entry of generics toward the end of the forecast period. Additionally, the most commercially promising emerging therapies that are anticipated to launch for multiple myeloma-carfilzomib and Celgene's pomalidomide-will command combined sales of nearly $800 million in 2020."

The Pharmacor advisory service entitled Multiple Myeloma, which will be published by the end of the month, finds that, despite the continued expansion of Takeda/Janssen-Cilag/Janssen's Velcade in the first-line setting, sales of Velcade will be rapidly eclipsed by Revlimid's dramatic growth. The approval of Revlimid in the first-line setting will also aggressively erode patient share and sales of Celgene's Thalidomide/Thalomid and Fujimoto Seiyaku's Thaled. In 2020, Revlimid will hold a 62 percent market share of the total myeloma market.

Revlimid and Velcade will experience increasing uptake in the relapsed/refractory setting as they will be used in combination with emerging therapies. Revlimid will be used in combination with Onyx Pharmaceuticals/Ono Pharmaceutical's carfilzomib, anticipated to be approved by the U.S. Food and Drug Administration as early as 2012, and Bristol-Myers Squibb/Abbott's elotuzumab, which will launch later (in 2015) in the United States and Europe. Velcade will also experience increased uptake in combination with AEterna Zentaris/Keryx Biopharmaceuticals/Yakult Honsha's perifosine, Merck & Co.'s Zolinza and Novartis's panobinostat.

"Overall, Revlimid will emerge as the clear market leader in the multiple myeloma market over the next decade," said Decision Resources Analyst Khurram Nawaz. "Velcade will remain the second highest selling agent but will suffer from the entry of generics toward the end of the forecast period. Additionally, the most commercially promising emerging therapies that are anticipated to launch for multiple myeloma-carfilzomib and Celgene's pomalidomide-will command combined sales of nearly $800 million in 2020."

The findings also reveal that significant opportunity lies in the development of agents that improve survival and reduce toxicities compared with currently available therapies. The launch of seven emerging therapies during the forecast period will partially fulfill the high unmet need.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Contacts

Decision Resources
Christopher Comfort, 781-993-2597
[email protected]

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.